Clinical Trial Update: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Eltrekibart and Mirikizumab in adults with moderately to severely active Ulcerative Colitis; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Eltrekibart (LY3041658)
• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic | Phase 2 | Status: RECRUITING